用第三代EGFR-TKI治疗的EGFR突变NSCLC患者的血代谢概况

Ning Lou1,2, Ruyun Gao3, Yuankai Shi4

  • 1Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College; No.1, Shuaifuyuan, Dongcheng District, Beijing, 100730, China.

Scientific data
|December 18, 2024
PubMed
概括

第三代EGFR-TKI显示出对非小细胞肺癌 (NSCLC) 的治疗有前途. 这项研究分析了血代谢物,以确定预测NSCLC患者治疗反应的生物标志物.